Back to Search Start Over

CDC’s COVID-19 International Vaccine Implementation and Evaluation Program and Lessons from Earlier Vaccine Introductions

Authors :
Heidi M. Soeters
Reena H. Doshi
Monica Fleming
Oluwasegun Joel Adegoke
Uzoamaka Ajene
Brooke Noel Aksnes
Sarah Bennett
Erin F. Blau
Julie Garon Carlton
Sara Clements
Laura Conklin
Melissa Dahlke
Lindsey M. Duca
Leora R. Feldstein
Jane F. Gidudu
Gavin Grant
Margaret Hercules
Ledor S. Igboh
Atsuyoshi Ishizumi
Sara Jacenko
Yinka Kerr
Nuadum M. Konne
Shibani Kulkarni
Archana Kumar
Kathryn E. Lafond
Eugene Lam
Ashley T. Longley
Margaret McCarron
Apophia Namageyo-Funa
Nancy Ortiz
Jaymin C. Patel
Robert T. Perry
Dimitri Prybylski
Prianca Reddi
Omar Salman
Courtney N. Sciarratta
Talya Shragai
Akshita Siddula
Ester Sikare
Dieula Delissaint Tchoualeu
Denise Traicoff
Alexandra Tuttle
Kerton R. Victory
Aaron Wallace
Kirsten Ward
Man Kai Alyssa Wong
Weigong Zhou
W. William Schluter
David L. Fitter
Anthony Mounts
Joseph S. Bresee
Terri B. Hyde
Source :
Emerging Infectious Diseases, Vol 28, Iss 13, Pp 208-216 (2022)
Publication Year :
2022
Publisher :
Centers for Disease Control and Prevention, 2022.

Abstract

The US Centers for Disease Control and Prevention (CDC) supports international partners in introducing vaccines, including those against SARS-CoV-2 virus. CDC contributes to the development of global technical tools, guidance, and policy for COVID-19 vaccination and has established its COVID-19 International Vaccine Implementation and Evaluation (CIVIE) program. CIVIE supports ministries of health and their partner organizations in developing or strengthening their national capacities for the planning, implementation, and evaluation of COVID-19 vaccination programs. CIVIE’s 7 priority areas for country-specific technical assistance are vaccine policy development, program planning, vaccine confidence and demand, data management and use, workforce development, vaccine safety, and evaluation. We discuss CDC’s work on global COVID-19 vaccine implementation, including priorities, challenges, opportunities, and applicable lessons learned from prior experiences with Ebola, influenza, and meningococcal serogroup A conjugate vaccine introductions.

Details

Language :
English
ISSN :
10806040 and 10806059
Volume :
28
Issue :
13
Database :
Directory of Open Access Journals
Journal :
Emerging Infectious Diseases
Publication Type :
Academic Journal
Accession number :
edsdoj.28160f7d8924c3fb7eb5a3ceaf22d3d
Document Type :
article
Full Text :
https://doi.org/10.3201/eid2813.212123